Drug profile · INN
filgrastim-txid
NYPOZI
filgrastim-txid (NYPOZI) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — filgrastim-txid
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
filgrastim-txid (NYPOZI) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is filgrastim-txid?
filgrastim-txid (NYPOZI) is a granulocyte colony stimulating factor receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for filgrastim-txid?
NYPOZI is a marketed brand name for filgrastim-txid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of filgrastim-txid?
filgrastim-txid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.